Review





Similar Products

94
OriGene immunohistochemical staining kit
Stromal CXCL12 associates with TLS enrichment in NSCLC-BM and improved outcomes with ICI therapy. (A) Bubble plots showing chemokine receptor expression levels in Microglia, B cells, and CD4-TCF1 T cells. (B) Bubble plots CXCL12 , CXCL13 , CCL19 , and CCL21 expression levels in NSCLC-BM samples. (C) Violin plots displaying the expression levels of CXCL12 and CXCL13 in tumours from TLS-low and TLS-high groups. TLS-low group, n = 12; TLS-high group, n = 13. P < 0.001 (∗∗∗). Dashed lines indicate the median and IQR. P -value was calculated using Mann–Whitney U test. P < 0.001 (∗∗∗). (D) Representative <t>IHC</t> images of CXCL12 staining in NSCLC-BM tissues. Scale bar = 100 μm. (E) The statistical results of CXCL12 IHC staining. Upper, Correlation between stromal CXCL12 expression and TLS scores.The stromal CXCL12 IRS scores of 0–6 were classified as low expression, whereas scores of 8–12 were classified as high expression. P -value was calculated using Pearson's chi-square test. Lower, the IRS of CXCL12 expression in paired stromal regions within and outside TLSs across 52 TLS-positive samples. Data are shown as individual values with mean ± SD. P -value was calculated using Wilcoxon test. (F) Bubble plot showing CXCL12 expression levels of different cell clusters. (G) Representative mIHC images of BM tissues stained with anti-CD20 (yellow), CD31 (red), FAP (magenta), and CXCL12 (green) antibodies. Upper, scale bar = 100 μm. Lower, scale bar = 10 μm. (H) Boxplots showing the fraction of CXCL12+ cells among CD31+ cells and FAP+ cells within TLSs across 52 TLS-positive samples. Data are presented as median with IQR. P -value was calculated using the Wilcoxon test. (I) Kaplan–Meier survival analysis for iPFS in patients with NSCLC-BM receiving postoperative ICIs (n = 29) according to CXCL12 IRS in intratumoral stroma. P -value was calculated using log-rank test. NSCLC-BM, non-small cell lung cancer brain metastasis; iPFS, intracranial progression-free survival; TLS, tertiary lymphoid structure; ICIs, immune checkpoint inhibitors; IRS, immunoreactivity scores.
Immunohistochemical Staining Kit, supplied by OriGene, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+anti+human+mr+antibody/Polink+DS-MR-Hu+A1+Kit+for+mouse+and+rabbit+antibody+on+human+tissue+with+DAB+%26+GBI-Permanent+Red/pmc13157008-100-11-14
Average 94 stars, based on 1 article reviews
immunohistochemical staining kit - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

94
OriGene two step staining kit
Stromal CXCL12 associates with TLS enrichment in NSCLC-BM and improved outcomes with ICI therapy. (A) Bubble plots showing chemokine receptor expression levels in Microglia, B cells, and CD4-TCF1 T cells. (B) Bubble plots CXCL12 , CXCL13 , CCL19 , and CCL21 expression levels in NSCLC-BM samples. (C) Violin plots displaying the expression levels of CXCL12 and CXCL13 in tumours from TLS-low and TLS-high groups. TLS-low group, n = 12; TLS-high group, n = 13. P < 0.001 (∗∗∗). Dashed lines indicate the median and IQR. P -value was calculated using Mann–Whitney U test. P < 0.001 (∗∗∗). (D) Representative <t>IHC</t> images of CXCL12 staining in NSCLC-BM tissues. Scale bar = 100 μm. (E) The statistical results of CXCL12 IHC staining. Upper, Correlation between stromal CXCL12 expression and TLS scores.The stromal CXCL12 IRS scores of 0–6 were classified as low expression, whereas scores of 8–12 were classified as high expression. P -value was calculated using Pearson's chi-square test. Lower, the IRS of CXCL12 expression in paired stromal regions within and outside TLSs across 52 TLS-positive samples. Data are shown as individual values with mean ± SD. P -value was calculated using Wilcoxon test. (F) Bubble plot showing CXCL12 expression levels of different cell clusters. (G) Representative mIHC images of BM tissues stained with anti-CD20 (yellow), CD31 (red), FAP (magenta), and CXCL12 (green) antibodies. Upper, scale bar = 100 μm. Lower, scale bar = 10 μm. (H) Boxplots showing the fraction of CXCL12+ cells among CD31+ cells and FAP+ cells within TLSs across 52 TLS-positive samples. Data are presented as median with IQR. P -value was calculated using the Wilcoxon test. (I) Kaplan–Meier survival analysis for iPFS in patients with NSCLC-BM receiving postoperative ICIs (n = 29) according to CXCL12 IRS in intratumoral stroma. P -value was calculated using log-rank test. NSCLC-BM, non-small cell lung cancer brain metastasis; iPFS, intracranial progression-free survival; TLS, tertiary lymphoid structure; ICIs, immune checkpoint inhibitors; IRS, immunoreactivity scores.
Two Step Staining Kit, supplied by OriGene, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+anti+human+mr+antibody/Polink+DS-MR-Hu+C2+Kit+for+mouse+and+rabbit+antibody+on+human+tissue+with+Emerald+and+GBI-Permanent+Red+for+co-localization/pm41494252-84-9-17
Average 94 stars, based on 1 article reviews
two step staining kit - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

93
OriGene ihc kit
Stromal CXCL12 associates with TLS enrichment in NSCLC-BM and improved outcomes with ICI therapy. (A) Bubble plots showing chemokine receptor expression levels in Microglia, B cells, and CD4-TCF1 T cells. (B) Bubble plots CXCL12 , CXCL13 , CCL19 , and CCL21 expression levels in NSCLC-BM samples. (C) Violin plots displaying the expression levels of CXCL12 and CXCL13 in tumours from TLS-low and TLS-high groups. TLS-low group, n = 12; TLS-high group, n = 13. P < 0.001 (∗∗∗). Dashed lines indicate the median and IQR. P -value was calculated using Mann–Whitney U test. P < 0.001 (∗∗∗). (D) Representative <t>IHC</t> images of CXCL12 staining in NSCLC-BM tissues. Scale bar = 100 μm. (E) The statistical results of CXCL12 IHC staining. Upper, Correlation between stromal CXCL12 expression and TLS scores.The stromal CXCL12 IRS scores of 0–6 were classified as low expression, whereas scores of 8–12 were classified as high expression. P -value was calculated using Pearson's chi-square test. Lower, the IRS of CXCL12 expression in paired stromal regions within and outside TLSs across 52 TLS-positive samples. Data are shown as individual values with mean ± SD. P -value was calculated using Wilcoxon test. (F) Bubble plot showing CXCL12 expression levels of different cell clusters. (G) Representative mIHC images of BM tissues stained with anti-CD20 (yellow), CD31 (red), FAP (magenta), and CXCL12 (green) antibodies. Upper, scale bar = 100 μm. Lower, scale bar = 10 μm. (H) Boxplots showing the fraction of CXCL12+ cells among CD31+ cells and FAP+ cells within TLSs across 52 TLS-positive samples. Data are presented as median with IQR. P -value was calculated using the Wilcoxon test. (I) Kaplan–Meier survival analysis for iPFS in patients with NSCLC-BM receiving postoperative ICIs (n = 29) according to CXCL12 IRS in intratumoral stroma. P -value was calculated using log-rank test. NSCLC-BM, non-small cell lung cancer brain metastasis; iPFS, intracranial progression-free survival; TLS, tertiary lymphoid structure; ICIs, immune checkpoint inhibitors; IRS, immunoreactivity scores.
Ihc Kit, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+anti+human+mr+antibody/Polink+DS-MR-Hu+A1+Kit+for+mouse+and+rabbit+antibody+on+human+tissue+with+DAB+%26+GBI-Permanent+Red/pmc12663271-118-1-3
Average 93 stars, based on 1 article reviews
ihc kit - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

93
OriGene immunohistochemistry detection kit
Stromal CXCL12 associates with TLS enrichment in NSCLC-BM and improved outcomes with ICI therapy. (A) Bubble plots showing chemokine receptor expression levels in Microglia, B cells, and CD4-TCF1 T cells. (B) Bubble plots CXCL12 , CXCL13 , CCL19 , and CCL21 expression levels in NSCLC-BM samples. (C) Violin plots displaying the expression levels of CXCL12 and CXCL13 in tumours from TLS-low and TLS-high groups. TLS-low group, n = 12; TLS-high group, n = 13. P < 0.001 (∗∗∗). Dashed lines indicate the median and IQR. P -value was calculated using Mann–Whitney U test. P < 0.001 (∗∗∗). (D) Representative <t>IHC</t> images of CXCL12 staining in NSCLC-BM tissues. Scale bar = 100 μm. (E) The statistical results of CXCL12 IHC staining. Upper, Correlation between stromal CXCL12 expression and TLS scores.The stromal CXCL12 IRS scores of 0–6 were classified as low expression, whereas scores of 8–12 were classified as high expression. P -value was calculated using Pearson's chi-square test. Lower, the IRS of CXCL12 expression in paired stromal regions within and outside TLSs across 52 TLS-positive samples. Data are shown as individual values with mean ± SD. P -value was calculated using Wilcoxon test. (F) Bubble plot showing CXCL12 expression levels of different cell clusters. (G) Representative mIHC images of BM tissues stained with anti-CD20 (yellow), CD31 (red), FAP (magenta), and CXCL12 (green) antibodies. Upper, scale bar = 100 μm. Lower, scale bar = 10 μm. (H) Boxplots showing the fraction of CXCL12+ cells among CD31+ cells and FAP+ cells within TLSs across 52 TLS-positive samples. Data are presented as median with IQR. P -value was calculated using the Wilcoxon test. (I) Kaplan–Meier survival analysis for iPFS in patients with NSCLC-BM receiving postoperative ICIs (n = 29) according to CXCL12 IRS in intratumoral stroma. P -value was calculated using log-rank test. NSCLC-BM, non-small cell lung cancer brain metastasis; iPFS, intracranial progression-free survival; TLS, tertiary lymphoid structure; ICIs, immune checkpoint inhibitors; IRS, immunoreactivity scores.
Immunohistochemistry Detection Kit, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+anti+human+mr+antibody/Polink+DS-MR-Hu+C1+Kit+for+mouse+and+rabbit+antibody+on+human+tissue+with+Emerald+and+GBI-Permanent+Red+for+Co-localization/pmc12477332-91-11-14
Average 93 stars, based on 1 article reviews
immunohistochemistry detection kit - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

93
OriGene polink ds mr hu c2 kit
Stromal CXCL12 associates with TLS enrichment in NSCLC-BM and improved outcomes with ICI therapy. (A) Bubble plots showing chemokine receptor expression levels in Microglia, B cells, and CD4-TCF1 T cells. (B) Bubble plots CXCL12 , CXCL13 , CCL19 , and CCL21 expression levels in NSCLC-BM samples. (C) Violin plots displaying the expression levels of CXCL12 and CXCL13 in tumours from TLS-low and TLS-high groups. TLS-low group, n = 12; TLS-high group, n = 13. P < 0.001 (∗∗∗). Dashed lines indicate the median and IQR. P -value was calculated using Mann–Whitney U test. P < 0.001 (∗∗∗). (D) Representative <t>IHC</t> images of CXCL12 staining in NSCLC-BM tissues. Scale bar = 100 μm. (E) The statistical results of CXCL12 IHC staining. Upper, Correlation between stromal CXCL12 expression and TLS scores.The stromal CXCL12 IRS scores of 0–6 were classified as low expression, whereas scores of 8–12 were classified as high expression. P -value was calculated using Pearson's chi-square test. Lower, the IRS of CXCL12 expression in paired stromal regions within and outside TLSs across 52 TLS-positive samples. Data are shown as individual values with mean ± SD. P -value was calculated using Wilcoxon test. (F) Bubble plot showing CXCL12 expression levels of different cell clusters. (G) Representative mIHC images of BM tissues stained with anti-CD20 (yellow), CD31 (red), FAP (magenta), and CXCL12 (green) antibodies. Upper, scale bar = 100 μm. Lower, scale bar = 10 μm. (H) Boxplots showing the fraction of CXCL12+ cells among CD31+ cells and FAP+ cells within TLSs across 52 TLS-positive samples. Data are presented as median with IQR. P -value was calculated using the Wilcoxon test. (I) Kaplan–Meier survival analysis for iPFS in patients with NSCLC-BM receiving postoperative ICIs (n = 29) according to CXCL12 IRS in intratumoral stroma. P -value was calculated using log-rank test. NSCLC-BM, non-small cell lung cancer brain metastasis; iPFS, intracranial progression-free survival; TLS, tertiary lymphoid structure; ICIs, immune checkpoint inhibitors; IRS, immunoreactivity scores.
Polink Ds Mr Hu C2 Kit, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+anti+human+mr+antibody/Polink+DS-MR-Hu+C2+Kit+for+mouse+and+rabbit+antibody+on+human+tissue+with+Emerald+and+GBI-Permanent+Red+for+co-localization/pmc12352432-82-23-27
Average 93 stars, based on 1 article reviews
polink ds mr hu c2 kit - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

93
OriGene staining kit
Stromal CXCL12 associates with TLS enrichment in NSCLC-BM and improved outcomes with ICI therapy. (A) Bubble plots showing chemokine receptor expression levels in Microglia, B cells, and CD4-TCF1 T cells. (B) Bubble plots CXCL12 , CXCL13 , CCL19 , and CCL21 expression levels in NSCLC-BM samples. (C) Violin plots displaying the expression levels of CXCL12 and CXCL13 in tumours from TLS-low and TLS-high groups. TLS-low group, n = 12; TLS-high group, n = 13. P < 0.001 (∗∗∗). Dashed lines indicate the median and IQR. P -value was calculated using Mann–Whitney U test. P < 0.001 (∗∗∗). (D) Representative <t>IHC</t> images of CXCL12 staining in NSCLC-BM tissues. Scale bar = 100 μm. (E) The statistical results of CXCL12 IHC staining. Upper, Correlation between stromal CXCL12 expression and TLS scores.The stromal CXCL12 IRS scores of 0–6 were classified as low expression, whereas scores of 8–12 were classified as high expression. P -value was calculated using Pearson's chi-square test. Lower, the IRS of CXCL12 expression in paired stromal regions within and outside TLSs across 52 TLS-positive samples. Data are shown as individual values with mean ± SD. P -value was calculated using Wilcoxon test. (F) Bubble plot showing CXCL12 expression levels of different cell clusters. (G) Representative mIHC images of BM tissues stained with anti-CD20 (yellow), CD31 (red), FAP (magenta), and CXCL12 (green) antibodies. Upper, scale bar = 100 μm. Lower, scale bar = 10 μm. (H) Boxplots showing the fraction of CXCL12+ cells among CD31+ cells and FAP+ cells within TLSs across 52 TLS-positive samples. Data are presented as median with IQR. P -value was calculated using the Wilcoxon test. (I) Kaplan–Meier survival analysis for iPFS in patients with NSCLC-BM receiving postoperative ICIs (n = 29) according to CXCL12 IRS in intratumoral stroma. P -value was calculated using log-rank test. NSCLC-BM, non-small cell lung cancer brain metastasis; iPFS, intracranial progression-free survival; TLS, tertiary lymphoid structure; ICIs, immune checkpoint inhibitors; IRS, immunoreactivity scores.
Staining Kit, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+anti+human+mr+antibody/Polink+DS-MR-Hu+C2+Kit+for+mouse+and+rabbit+antibody+on+human+tissue+with+Emerald+and+GBI-Permanent+Red+for+co-localization/pmc11995998-83-26-28
Average 93 stars, based on 1 article reviews
staining kit - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

93
OriGene polymer double staining kit
Stromal CXCL12 associates with TLS enrichment in NSCLC-BM and improved outcomes with ICI therapy. (A) Bubble plots showing chemokine receptor expression levels in Microglia, B cells, and CD4-TCF1 T cells. (B) Bubble plots CXCL12 , CXCL13 , CCL19 , and CCL21 expression levels in NSCLC-BM samples. (C) Violin plots displaying the expression levels of CXCL12 and CXCL13 in tumours from TLS-low and TLS-high groups. TLS-low group, n = 12; TLS-high group, n = 13. P < 0.001 (∗∗∗). Dashed lines indicate the median and IQR. P -value was calculated using Mann–Whitney U test. P < 0.001 (∗∗∗). (D) Representative <t>IHC</t> images of CXCL12 staining in NSCLC-BM tissues. Scale bar = 100 μm. (E) The statistical results of CXCL12 IHC staining. Upper, Correlation between stromal CXCL12 expression and TLS scores.The stromal CXCL12 IRS scores of 0–6 were classified as low expression, whereas scores of 8–12 were classified as high expression. P -value was calculated using Pearson's chi-square test. Lower, the IRS of CXCL12 expression in paired stromal regions within and outside TLSs across 52 TLS-positive samples. Data are shown as individual values with mean ± SD. P -value was calculated using Wilcoxon test. (F) Bubble plot showing CXCL12 expression levels of different cell clusters. (G) Representative mIHC images of BM tissues stained with anti-CD20 (yellow), CD31 (red), FAP (magenta), and CXCL12 (green) antibodies. Upper, scale bar = 100 μm. Lower, scale bar = 10 μm. (H) Boxplots showing the fraction of CXCL12+ cells among CD31+ cells and FAP+ cells within TLSs across 52 TLS-positive samples. Data are presented as median with IQR. P -value was calculated using the Wilcoxon test. (I) Kaplan–Meier survival analysis for iPFS in patients with NSCLC-BM receiving postoperative ICIs (n = 29) according to CXCL12 IRS in intratumoral stroma. P -value was calculated using log-rank test. NSCLC-BM, non-small cell lung cancer brain metastasis; iPFS, intracranial progression-free survival; TLS, tertiary lymphoid structure; ICIs, immune checkpoint inhibitors; IRS, immunoreactivity scores.
Polymer Double Staining Kit, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+anti+human+mr+antibody/Polink+DS-MR-Hu+C2+Kit+for+mouse+and+rabbit+antibody+on+human+tissue+with+Emerald+and+GBI-Permanent+Red+for+co-localization/pm40199876-218-2-5
Average 93 stars, based on 1 article reviews
polymer double staining kit - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

94
OriGene immunohistochemical kit
Figure 2 GBD can effectively improve the matrix degradation in IVDD model mice. (A–C) ECM components (AGC, COL II) and corresponding degrading enzymes (ADAMTS- 5 and MMP13) in IVDs tissues of IVDD mice were determined by IHC analysis. The black arrow indicates the positive expression. The red box indicates NP, the purple box indicates AF and the blue box indicates CEP. Data are expressed as mean ± SD, **Denotes a significant difference compared with the Sham group (**P < 0.01); #Means a significant difference compared with the LSI group (#P < 0.05, ##P < 0.01); †Indicates a significant difference compared with the LST group (†P < 0.05, ††P < 0.01); aDenotes a significant difference compared with the GBD-L group (aP < 0.05, aaP < 0.01 vs); bbIndicates a significant difference compared with the GBD-M group (bbP < 0.01); n = 6 per group. Abbreviations: GBD, Gubi decoction; ECM, extracellular matrix; IVD, Intervertebral disc; LSI, lumbar spine instability; LST, loxoprofen sodium tablets; NP, Nucleus pulposus; AF, annulus fibrosus; CEP, cartilage endplate; ADAMTS-5, ADAM metallopeptidase with thrombospondin type 1 motif 5; AGC, Aggrecan; COL II, Collagen II; MMP13, matrix metalloproteinase 13; IHC, <t>Immunohistochemical.</t>
Immunohistochemical Kit, supplied by OriGene, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+anti+human+mr+antibody/Polink+DS-MR-Hu+A1+Kit+for+mouse+and+rabbit+antibody+on+human+tissue+with+DAB+%26+GBI-Permanent+Red/10__2147_slash_jir__s492365-37-0-7
Average 94 stars, based on 1 article reviews
immunohistochemical kit - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

94
OriGene two step immunohistochemistry staining kit
Figure 2 GBD can effectively improve the matrix degradation in IVDD model mice. (A–C) ECM components (AGC, COL II) and corresponding degrading enzymes (ADAMTS- 5 and MMP13) in IVDs tissues of IVDD mice were determined by IHC analysis. The black arrow indicates the positive expression. The red box indicates NP, the purple box indicates AF and the blue box indicates CEP. Data are expressed as mean ± SD, **Denotes a significant difference compared with the Sham group (**P < 0.01); #Means a significant difference compared with the LSI group (#P < 0.05, ##P < 0.01); †Indicates a significant difference compared with the LST group (†P < 0.05, ††P < 0.01); aDenotes a significant difference compared with the GBD-L group (aP < 0.05, aaP < 0.01 vs); bbIndicates a significant difference compared with the GBD-M group (bbP < 0.01); n = 6 per group. Abbreviations: GBD, Gubi decoction; ECM, extracellular matrix; IVD, Intervertebral disc; LSI, lumbar spine instability; LST, loxoprofen sodium tablets; NP, Nucleus pulposus; AF, annulus fibrosus; CEP, cartilage endplate; ADAMTS-5, ADAM metallopeptidase with thrombospondin type 1 motif 5; AGC, Aggrecan; COL II, Collagen II; MMP13, matrix metalloproteinase 13; IHC, <t>Immunohistochemical.</t>
Two Step Immunohistochemistry Staining Kit, supplied by OriGene, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+anti+human+mr+antibody/Polink+DS-MR-Hu+A1+Kit+for+mouse+and+rabbit+antibody+on+human+tissue+with+DAB+%26+GBI-Permanent+Red/pm39672028-112-17-22
Average 94 stars, based on 1 article reviews
two step immunohistochemistry staining kit - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

92
OriGene immunohistochemical kits
Figure 2 GBD can effectively improve the matrix degradation in IVDD model mice. (A–C) ECM components (AGC, COL II) and corresponding degrading enzymes (ADAMTS- 5 and MMP13) in IVDs tissues of IVDD mice were determined by IHC analysis. The black arrow indicates the positive expression. The red box indicates NP, the purple box indicates AF and the blue box indicates CEP. Data are expressed as mean ± SD, **Denotes a significant difference compared with the Sham group (**P < 0.01); #Means a significant difference compared with the LSI group (#P < 0.05, ##P < 0.01); †Indicates a significant difference compared with the LST group (†P < 0.05, ††P < 0.01); aDenotes a significant difference compared with the GBD-L group (aP < 0.05, aaP < 0.01 vs); bbIndicates a significant difference compared with the GBD-M group (bbP < 0.01); n = 6 per group. Abbreviations: GBD, Gubi decoction; ECM, extracellular matrix; IVD, Intervertebral disc; LSI, lumbar spine instability; LST, loxoprofen sodium tablets; NP, Nucleus pulposus; AF, annulus fibrosus; CEP, cartilage endplate; ADAMTS-5, ADAM metallopeptidase with thrombospondin type 1 motif 5; AGC, Aggrecan; COL II, Collagen II; MMP13, matrix metalloproteinase 13; IHC, <t>Immunohistochemical.</t>
Immunohistochemical Kits, supplied by OriGene, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+anti+human+mr+antibody/Polink+DS-MR-Hu+B1+Kit+for+mouse+and+rabbit+antibody+on+human+tissue+with+BCIP%2FNBT+%26+AEC/ppr0925242-61-0-5
Average 92 stars, based on 1 article reviews
immunohistochemical kits - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier

Image Search Results


Stromal CXCL12 associates with TLS enrichment in NSCLC-BM and improved outcomes with ICI therapy. (A) Bubble plots showing chemokine receptor expression levels in Microglia, B cells, and CD4-TCF1 T cells. (B) Bubble plots CXCL12 , CXCL13 , CCL19 , and CCL21 expression levels in NSCLC-BM samples. (C) Violin plots displaying the expression levels of CXCL12 and CXCL13 in tumours from TLS-low and TLS-high groups. TLS-low group, n = 12; TLS-high group, n = 13. P < 0.001 (∗∗∗). Dashed lines indicate the median and IQR. P -value was calculated using Mann–Whitney U test. P < 0.001 (∗∗∗). (D) Representative IHC images of CXCL12 staining in NSCLC-BM tissues. Scale bar = 100 μm. (E) The statistical results of CXCL12 IHC staining. Upper, Correlation between stromal CXCL12 expression and TLS scores.The stromal CXCL12 IRS scores of 0–6 were classified as low expression, whereas scores of 8–12 were classified as high expression. P -value was calculated using Pearson's chi-square test. Lower, the IRS of CXCL12 expression in paired stromal regions within and outside TLSs across 52 TLS-positive samples. Data are shown as individual values with mean ± SD. P -value was calculated using Wilcoxon test. (F) Bubble plot showing CXCL12 expression levels of different cell clusters. (G) Representative mIHC images of BM tissues stained with anti-CD20 (yellow), CD31 (red), FAP (magenta), and CXCL12 (green) antibodies. Upper, scale bar = 100 μm. Lower, scale bar = 10 μm. (H) Boxplots showing the fraction of CXCL12+ cells among CD31+ cells and FAP+ cells within TLSs across 52 TLS-positive samples. Data are presented as median with IQR. P -value was calculated using the Wilcoxon test. (I) Kaplan–Meier survival analysis for iPFS in patients with NSCLC-BM receiving postoperative ICIs (n = 29) according to CXCL12 IRS in intratumoral stroma. P -value was calculated using log-rank test. NSCLC-BM, non-small cell lung cancer brain metastasis; iPFS, intracranial progression-free survival; TLS, tertiary lymphoid structure; ICIs, immune checkpoint inhibitors; IRS, immunoreactivity scores.

Journal: eBioMedicine

Article Title: TCF1+CD4+ T cells and microglia co-orchestrate tertiary lymphoid structures to enhance prognosis and immunotherapy in non-small cell lung cancer with brain metastases

doi: 10.1016/j.ebiom.2026.106280

Figure Lengend Snippet: Stromal CXCL12 associates with TLS enrichment in NSCLC-BM and improved outcomes with ICI therapy. (A) Bubble plots showing chemokine receptor expression levels in Microglia, B cells, and CD4-TCF1 T cells. (B) Bubble plots CXCL12 , CXCL13 , CCL19 , and CCL21 expression levels in NSCLC-BM samples. (C) Violin plots displaying the expression levels of CXCL12 and CXCL13 in tumours from TLS-low and TLS-high groups. TLS-low group, n = 12; TLS-high group, n = 13. P < 0.001 (∗∗∗). Dashed lines indicate the median and IQR. P -value was calculated using Mann–Whitney U test. P < 0.001 (∗∗∗). (D) Representative IHC images of CXCL12 staining in NSCLC-BM tissues. Scale bar = 100 μm. (E) The statistical results of CXCL12 IHC staining. Upper, Correlation between stromal CXCL12 expression and TLS scores.The stromal CXCL12 IRS scores of 0–6 were classified as low expression, whereas scores of 8–12 were classified as high expression. P -value was calculated using Pearson's chi-square test. Lower, the IRS of CXCL12 expression in paired stromal regions within and outside TLSs across 52 TLS-positive samples. Data are shown as individual values with mean ± SD. P -value was calculated using Wilcoxon test. (F) Bubble plot showing CXCL12 expression levels of different cell clusters. (G) Representative mIHC images of BM tissues stained with anti-CD20 (yellow), CD31 (red), FAP (magenta), and CXCL12 (green) antibodies. Upper, scale bar = 100 μm. Lower, scale bar = 10 μm. (H) Boxplots showing the fraction of CXCL12+ cells among CD31+ cells and FAP+ cells within TLSs across 52 TLS-positive samples. Data are presented as median with IQR. P -value was calculated using the Wilcoxon test. (I) Kaplan–Meier survival analysis for iPFS in patients with NSCLC-BM receiving postoperative ICIs (n = 29) according to CXCL12 IRS in intratumoral stroma. P -value was calculated using log-rank test. NSCLC-BM, non-small cell lung cancer brain metastasis; iPFS, intracranial progression-free survival; TLS, tertiary lymphoid structure; ICIs, immune checkpoint inhibitors; IRS, immunoreactivity scores.

Article Snippet: IHC staining was performed using the SP method, employing the universal immunohistochemical staining kit (Zhongshan Golden Bridge Biotechnology; Cat# PV-6000) and DAB chromogen kit (Zhongshan Golden Bridge Biotechnology; Cat# PV-6000D).

Techniques: Expressing, MANN-WHITNEY, Staining, Immunohistochemistry

Figure 2 GBD can effectively improve the matrix degradation in IVDD model mice. (A–C) ECM components (AGC, COL II) and corresponding degrading enzymes (ADAMTS- 5 and MMP13) in IVDs tissues of IVDD mice were determined by IHC analysis. The black arrow indicates the positive expression. The red box indicates NP, the purple box indicates AF and the blue box indicates CEP. Data are expressed as mean ± SD, **Denotes a significant difference compared with the Sham group (**P < 0.01); #Means a significant difference compared with the LSI group (#P < 0.05, ##P < 0.01); †Indicates a significant difference compared with the LST group (†P < 0.05, ††P < 0.01); aDenotes a significant difference compared with the GBD-L group (aP < 0.05, aaP < 0.01 vs); bbIndicates a significant difference compared with the GBD-M group (bbP < 0.01); n = 6 per group. Abbreviations: GBD, Gubi decoction; ECM, extracellular matrix; IVD, Intervertebral disc; LSI, lumbar spine instability; LST, loxoprofen sodium tablets; NP, Nucleus pulposus; AF, annulus fibrosus; CEP, cartilage endplate; ADAMTS-5, ADAM metallopeptidase with thrombospondin type 1 motif 5; AGC, Aggrecan; COL II, Collagen II; MMP13, matrix metalloproteinase 13; IHC, Immunohistochemical.

Journal: Journal of Inflammation Research

Article Title: Gubi Decoction Ameliorates Porous Cartilage Endplate in an Intervertebral Disc Degeneration Model Mouse Through Inhibition of NF-κB Activity and Pyroptosis

doi: 10.2147/jir.s492365

Figure Lengend Snippet: Figure 2 GBD can effectively improve the matrix degradation in IVDD model mice. (A–C) ECM components (AGC, COL II) and corresponding degrading enzymes (ADAMTS- 5 and MMP13) in IVDs tissues of IVDD mice were determined by IHC analysis. The black arrow indicates the positive expression. The red box indicates NP, the purple box indicates AF and the blue box indicates CEP. Data are expressed as mean ± SD, **Denotes a significant difference compared with the Sham group (**P < 0.01); #Means a significant difference compared with the LSI group (#P < 0.05, ##P < 0.01); †Indicates a significant difference compared with the LST group (†P < 0.05, ††P < 0.01); aDenotes a significant difference compared with the GBD-L group (aP < 0.05, aaP < 0.01 vs); bbIndicates a significant difference compared with the GBD-M group (bbP < 0.01); n = 6 per group. Abbreviations: GBD, Gubi decoction; ECM, extracellular matrix; IVD, Intervertebral disc; LSI, lumbar spine instability; LST, loxoprofen sodium tablets; NP, Nucleus pulposus; AF, annulus fibrosus; CEP, cartilage endplate; ADAMTS-5, ADAM metallopeptidase with thrombospondin type 1 motif 5; AGC, Aggrecan; COL II, Collagen II; MMP13, matrix metalloproteinase 13; IHC, Immunohistochemical.

Article Snippet: Immunohistochemical kit (Cat# PV9001) was purchased from Zhongshan Golden Bridge Biotechnology Co., Ltd. (China) and Dylight 488 conjugated Goat Anti Rabbit IgG (Cat# RS23220) was from Immunoway.

Techniques: Expressing, Immunohistochemical staining